Neonatal sepsis, defi ned as sepsis occurring within the fi rst 28 days of life, is associated with signifi cant morbidity and mortality. It is undeniable that fi nding and appliance of biomarkers in clinical practice is of great importance, aiming at the early recognition of the impending clinical deterioration and the prompt and targeted therapeutic intervention. Aft er systematic and thorough research of the limited relevant literature, we attempt to present a documented point-of-view on the diagnostic value of TREM-1 and its soluble form both in early and late onset neonatal sepsis.